The future of cancer immunotherapy: microenvironment-targeting combinations
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The future of cancer immunotherapy: microenvironment-targeting combinations
Authors
Keywords
-
Journal
CELL RESEARCH
Volume 30, Issue 6, Pages 507-519
Publisher
Springer Science and Business Media LLC
Online
2020-05-28
DOI
10.1038/s41422-020-0337-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma
- (2019) Young K. Hong et al. CELLULAR IMMUNOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
- (2019) Gaia Griguolo et al. Journal for ImmunoTherapy of Cancer
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Modulating the microbiome to improve therapeutic response in cancer
- (2019) Jennifer L McQuade et al. LANCET ONCOLOGY
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy
- (2019) William J. Murphy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy
- (2019) Hany A. Omar et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?
- (2019) Xiaojie Zhang et al. CANCER RESEARCH
- Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
- (2019) Amod Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
- (2019) David Michael Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.
- (2019) Kartik Anand et al. JOURNAL OF CLINICAL ONCOLOGY
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
- (2019) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
- (2019) Weimin Wang et al. NATURE
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation
- (2019) Diana Vara-Ciruelos et al. Cell Reports
- T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
- (2019) Smita S. Chandran et al. IMMUNOLOGICAL REVIEWS
- Phenformin as an Anticancer Agent: Challenges and Prospects
- (2019) Rubiño et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity
- (2019) Mario Martínez Soldevilla et al. MOLECULAR THERAPY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome
- (2019) Allison Betof Warner et al. Current Oncology Reports
- Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
- (2019) Gerald P. Linette et al. Current Hematologic Malignancy Reports
- Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor
- (2019) Dehong Yan et al. Frontiers in Immunology
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Monocarboxylate transporters in cancer
- (2019) Valéry L. Payen et al. Molecular Metabolism
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11
- (2019) Xueting Lang et al. Cancer Discovery
- Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
- (2019) Antonio Marchini et al. Frontiers in Immunology
- Management of V600E and V600K BRAF-Mutant Melanoma
- (2019) Alexandra M. Haugh et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
- (2018) G K Abou-Alfa et al. ANNALS OF ONCOLOGY
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
- (2018) Vancheswaran Gopalakrishnan et al. CANCER CELL
- LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
- (2018) Masoud F. Tavazoie et al. CELL
- Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer
- (2018) Wei Li et al. Cell Metabolism
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- T-cell responses toTP53"hotspot" mutations and unique neoantigens expressed by human ovarian cancers
- (2018) Drew C Deniger et al. CLINICAL CANCER RESEARCH
- Antigen Presentation Keeps Trending in Immunotherapy Resistance
- (2018) Anusha Kalbasi et al. CLINICAL CANCER RESEARCH
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- The intestinal microbiome influences checkpoint blockade
- (2018) Cynthia L Sears et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision medicine using microbiota
- (2018) Christian Jobin SCIENCE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?
- (2018) Malini Patel et al. Journal of Thoracic Disease
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
- (2018) Felix S. Lichtenegger et al. Frontiers in Immunology
- Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
- (2018) Natalia Pieper et al. OncoImmunology
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
- (2018) Sun-Hee Kim et al. Frontiers in Oncology
- Role of mTOR Signaling in Tumor Microenvironment: An Overview
- (2018) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer
- (2018) Jessica J. Lin et al. Journal of Thoracic Oncology
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy
- (2018) Lingyun Li et al. Cell Metabolism
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
- (2018) Maartje W. Rohaan et al. Journal for ImmunoTherapy of Cancer
- Cutting Edge: Anti–TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice
- (2017) Takuma Isshiki et al. JOURNAL OF IMMUNOLOGY
- Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
- (2017) Sun Hye Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- Combining Epigenetic and Immunotherapy to Combat Cancer
- (2016) Katherine B. Chiappinelli et al. CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Talimogene Laherparepvec for the Treatment of Advanced Melanoma
- (2016) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
- (2016) R. Andersen et al. CLINICAL CANCER RESEARCH
- Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
- (2016) George A. Dominguez et al. CLINICAL CANCER RESEARCH
- The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
- (2016) Pedro N Aguiar et al. Immunotherapy
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- (2016) Stephanie L. Goff et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
- (2016) Seongseok Yun et al. Cancer Medicine
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
- (2016) Alexander S. Baras et al. OncoImmunology
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
- (2016) Rikke B. Holmgaard et al. EBioMedicine
- The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
- (2016) Shuo Zhang et al. PLoS One
- ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
- (2015) Juan R. Cubillos-Ruiz et al. CELL
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
- (2015) Kevin J Harrington et al. Expert Review of Anticancer Therapy
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
- (2015) K Cao et al. ONCOGENE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
- (2015) Michael A. Postow et al. Journal for ImmunoTherapy of Cancer
- Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
- (2015) Agnes S. Klar et al. PLoS One
- The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells
- (2014) Stefania Orecchioni et al. INTERNATIONAL JOURNAL OF CANCER
- ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis
- (2014) Thomas Condamine et al. JOURNAL OF CLINICAL INVESTIGATION
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
- (2014) Jing Lu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
- (2014) David A Schaer et al. Journal for ImmunoTherapy of Cancer
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
- (2013) C. J. Breitbach et al. CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
- (2013) P. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- Genetic cancer vaccines: current status and perspectives
- (2012) Luigi Aurisicchio et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
- (2012) Patrick A. Ott et al. INVESTIGATIONAL NEW DRUGS
- Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
- (2012) Pasquale Sansone et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
- (2011) M. Rao et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
- (2011) R. W. Joseph et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search